Results 161 to 170 of about 5,351,550 (365)

Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs [PDF]

, 2018
While approximately one in ten Americans suffers from a rare disease, only 5 percent of rare diseases have a U.S. Food and Drug Administration (FDA) approved treatment.
Bannister, Julien B.
core   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

From Concept to Regulatory Drug Approval: Lessons for Theranostics. [PDF]

J Nucl Med, 2022
Perera M, Morris MJ.
europepmc   +1 more source

Drugs approval process gets speed treatment [PDF]

, 2001
Erica Klarreich
openalex   +1 more source

A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA

, 2014
Developing a new drug requires great amount of research work in chemistry, manufacturing, controls, preclinical science and clinical trials. Drug reviewers in regulatory agencies around the world bear the responsibility of evaluating whether the research
Vishal Prajapati, R. Goswami, Pratik Makvana, J. K. Badjatya   +3 more
semanticscholar   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness. [PDF]

Int J Environ Res Public Health, 2023
Abdin AY, De Pretis F, Landes J.
europepmc   +1 more source

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source

Dostarlimab: From preclinical investigation to drug approval and future directions. [PDF]

Hum Vaccin Immunother, 2023
Cicala CM, Musacchio L, Scambia G, Lorusso D.   +3 more
europepmc   +1 more source

FDA Drug Approval Summaries: Fulvestrant [PDF]

, 2002
Peter Bross, Martin H. Cohen, Grant A. Williams, Richard Pazdur   +3 more
openalex   +1 more source